<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cidofovir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cidofovir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cidofovir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9264" href="/d/html/9264.html" rel="external">see "Cidofovir: Drug information"</a> and <a class="drug drug_patient" data-topicid="12362" href="/d/html/12362.html" rel="external">see "Cidofovir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708672"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Renal impairment is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as 1 or 2 doses of cidofovir. To reduce possible nephrotoxicity, IV prehydration with normal saline and administration of probenecid must be used with each cidofovir infusion. Renal function (serum creatinine and urine protein) must be monitored within 48 hours prior to each dose of cidofovir and the dose of cidofovir modified for changes in renal function as appropriate. Cidofovir is contraindicated in patients who are receiving other nephrotoxic agents.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neutropenia:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Neutropenia has been observed in association with cidofovir treatment. Therefore, neutrophil counts should be monitored during cidofovir therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Cidofovir is indicated only for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Carcinogenic/teratogenic:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">In animal studies, cidofovir was carcinogenic, teratogenic and caused hypospermia. </p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866334"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mar-Cidofovir</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046274"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent, Parenteral</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812491"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Route of administration varies (ie, IV, intravesicular, intralesional, topical); use caution to ensure dosing corresponds to appropriate route. Administration of cidofovir should be accompanied by concomitant oral probenecid and IV normal saline hydration, except in cases where lower doses are used and the site of infection is in the kidney or bladder; various regimens have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18307672','lexi-content-ref-30859626','lexi-content-ref-19392729','lexi-content-ref-25733509','lexi-content-ref-16157264','lexi-content-ref-17845926','lexi-content-ref-25010830','lexi-content-ref-32404785','lexi-content-ref-19801951','lexi-content-ref-16732176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18307672','lexi-content-ref-30859626','lexi-content-ref-19392729','lexi-content-ref-25733509','lexi-content-ref-16157264','lexi-content-ref-17845926','lexi-content-ref-25010830','lexi-content-ref-32404785','lexi-content-ref-19801951','lexi-content-ref-16732176'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Adjunctive therapies: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hydration:</i> IV (various regimens reported): 10 to 20 mL/kg of sodium chloride 0.9% (maximum: 1,000 mL) administered for 1 hour before cidofovir infusion and 10 to 20 mL/kg of sodium chloride 0.9% (maximum: 1,000 mL) over 1 hour during cidofovir infusion, followed by 2 hours of maintenance fluids <b>or </b>5 mL/kg/hour of sodium chloride 0.9% from 3 hours before cidofovir until 3 hours after <b>or</b> increase the maintenance fluid infusion rate to 3 times the maintenance rate for 1 hour before cidofovir infusion and continuing until 1 hour after, then decrease to 2 times the maintenance fluid rate for the subsequent 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Probenecid:</i> Oral: 25 to 40 mg/kg/dose (maximum dose: 2,000 mg) administered 3 hours before cidofovir infusion and 10 to 20 mg/kg/dose (maximum dose: 1,000 mg) at 2 to 3 hours and 8 to 9 hours after cidofovir infusion <b>or</b> 1,000 or 1,250 mg/m<sup>2</sup>/dose administered 3 hours prior to cidofovir, followed by 500 to 1,250 mg/m<sup>2</sup>/dose 1 to 3 hours and 8 hours after completion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5c584eb-e1c7-46bb-9369-951500002ea5">Adenovirus infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adenovirus infection (treatment or preemptive therapy): </b>Limited data available; optimal dose unknown; specific regimens may vary; consult institutional protocols. <b>Note: </b>Typically reserved for patients with disseminated, severe, or progressive disease or as preemptive therapy in hematopoietic cell transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30859626','lexi-content-ref-23146063','lexi-content-ref-32404785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30859626','lexi-content-ref-23146063','lexi-content-ref-32404785'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 5 mg/kg/dose once weekly <b>or</b> 5 mg/kg/dose once weekly for 2 doses then 5 mg/kg/dose every 2 weeks <b>or</b> 1 mg/kg/dose 3 times weekly; use with concomitant probenecid and hydration. Treatment duration is patient-specific and depends on various factors, including symptom resolution, immune recovery, and follow-up adenoviral testing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18307672','lexi-content-ref-19747629','lexi-content-ref-30859626','lexi-content-ref-27239277','lexi-content-ref-23146063','lexi-content-ref-32404785','lexi-content-ref-28419263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18307672','lexi-content-ref-19747629','lexi-content-ref-30859626','lexi-content-ref-27239277','lexi-content-ref-23146063','lexi-content-ref-32404785','lexi-content-ref-28419263'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cfa130b5-b1d6-4626-a99e-fdd88a3a3e0c">BK virus infection; allograft nephropathy in kidney transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>BK virus infection; allograft nephropathy in kidney transplant recipients (adjunct to reduction of immune suppression [if appropriate]):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 0.25 to 1 mg/kg/dose every 1 to 3 weeks without probenecid. Pediatric case series report use every 2 to 3 weeks with a most common starting dose of 0.25 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18537898','lexi-content-ref-19344337','lexi-content-ref-30859620','lexi-content-ref-12544881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18537898','lexi-content-ref-19344337','lexi-content-ref-30859620','lexi-content-ref-12544881'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ed779f9-8c52-4587-8d48-ce6dd14faacc">BK virus infection; hemorrhagic cystitis in hematopoietic cell transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>BK virus infection; hemorrhagic cystitis in hematopoietic cell transplant recipients:</b> Limited data available; optimal dose unknown:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IV:</i> Infants, Children, and Adolescents: 3 to 5 mg/kg/dose every 1 to 2 weeks with concomitant probenecid <b>or</b> 0.5 to 1.5 mg/kg/dose once weekly without probenecid; described treatment duration varies and is dependent on clinical response and/or viral clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19522651','lexi-content-ref-23222380','lexi-content-ref-29190347','lexi-content-ref-19057462','lexi-content-ref-33661334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19522651','lexi-content-ref-23222380','lexi-content-ref-29190347','lexi-content-ref-19057462','lexi-content-ref-33661334'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intravesicular:</i> Children ≥5 years and Adolescents: 5 mg/kg/dose (in 50 to 100 mL of NS) instilled into bladder once weekly; retain for ≥1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29388318','lexi-content-ref-29776868','lexi-content-ref-22999487','lexi-content-ref-25882393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29388318','lexi-content-ref-29776868','lexi-content-ref-22999487','lexi-content-ref-25882393'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="037f5d2a-2c98-496a-aa3d-cc77f156c749">Cytomegalovirus infection; treatment or preemptive therapy in immunocompromised patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV) infection; treatment or preemptive therapy in immunocompromised patients (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 5 mg/kg/dose once weekly for 2 consecutive weeks followed by 5 mg/kg/dose once every 2 weeks, in combination with probenecid. Duration depends on patient response and degree of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-16157264','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-29860512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-16157264','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-29860512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients who are HIV exposed/infected, continue chronic maintenance therapy/secondary prophylaxis (with ganciclovir, valganciclovir, or foscarnet as appropriate) until patient has been receiving antiretroviral therapy for ≥6 months and achieves age-specific CD4 cell count targets for ≥6 months duration (age &lt;6 years: CD4 percentage ≥15%; age ≥6 years: &gt;100 cells/mm<sup>3 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46f3fb05-3be4-44b7-9941-8dae4956899d">Herpes simplex virus infection, mucocutaneous, acyclovir-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus infection, mucocutaneous, acyclovir-resistant (alternative agent):</b> Very limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Children and Adolescents: 5 mg/kg/dose once weekly for 3 weeks, then 5 mg/kg/dose every 1 to 2 weeks if indicated; use in combination with probenecid. Duration dependent on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17461998','lexi-content-ref-11081393','lexi-content-ref-11734717','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17461998','lexi-content-ref-11081393','lexi-content-ref-11734717','lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Topical: Adolescents: Apply cidofovir 1% gel (extemporaneously prepared by a compounding pharmacy) 1 to 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2'])">Ref</a></span>). Duration is based on clinical response; prolonged duration of 21 to 28 days or longer may be required for patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f38fd0a-6d8f-4d43-9635-a4a80c9821f4">Respiratory papillomatosis, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory papillomatosis, recurrent (adjunctive therapy):</b> Limited data available; treatment protocols variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Intralesional: Dosage, volume, and number of injections per treatment variable based on extent of disease and size of airway: Commonly reported as 0.1 to 4 mL per treatment session injected intralesionally using a 5 mg/mL solution every 2 to 6 weeks. Concentrations reported in the literature vary from 2.5 mg/mL to 10 mg/mL; recommended volumes are ≤2 mL for children and ≤4 mL for adolescents; larger volumes have been reported. Maximum dose per session: 3 mg/kg/dose. Longer intervals between doses have also been reported (eg, every 3 to 4 months or as needed) based upon extent and recurrence of disease. Continue therapy until complete response; reported durations variable; a trial of 5 treatments is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23113383','lexi-content-ref-23070868','lexi-content-ref-15545589','lexi-content-ref-18700421','lexi-content-ref-28231366','lexi-content-ref-17044537','lexi-content-ref-12972938','lexi-content-ref-21519834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23113383','lexi-content-ref-23070868','lexi-content-ref-15545589','lexi-content-ref-18700421','lexi-content-ref-28231366','lexi-content-ref-17044537','lexi-content-ref-12972938','lexi-content-ref-21519834'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729638"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Adenovirus infection: Limited data available; specific protocols vary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859626','lexi-content-ref-20467354','lexi-content-ref-25010830','lexi-content-ref-32404785','lexi-content-ref-16732176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859626','lexi-content-ref-20467354','lexi-content-ref-25010830','lexi-content-ref-32404785','lexi-content-ref-16732176'])">Ref</a></span>). Based on a usual dose of 5 mg/kg/dose once weekly:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;90 mL/minute/1.73 m<sup>2</sup>, S<sub>cr</sub> &gt;1.5 mg/dL, CrCl &lt;0.3 mL/minute/<b>kg</b>, or &gt;2+ proteinuria: IV: Reduce dose to 0.5 to 1 mg/kg/dose 3 times weekly on alternate days for 2 weeks; may then decrease to 0.5 to 1 mg/kg/dose every other week.</p>
<p style="text-indent:-2em;margin-left:4em;">Other uses: There are no pediatric-specific recommendations for other uses; based on experience with other indications and in adult patients, dosing adjustment suggested.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis: </b>High flux hemodialysis removes ~50% to 75% based on adult data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9951427','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9951427','lexi-content-ref-Manu.1'])">Ref</a></span>). In pediatric solid organ transplant recipients with adenovirus, it has been recommended to administer dose ≥1 hour after and/or ≥4 hours before hemodialysis to allow for intracellular cidofovir distribution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20467354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20467354'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F52729639"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F151291"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9264" href="/d/html/9264.html" rel="external">see "Cidofovir: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>To minimize the likelihood of nephrotoxicity, unless otherwise indicated, premedicate with probenecid 2 g 3 hours prior to the cidofovir dose, then 1 g 2 hours and 8 hours after completion of the infusion. Patients should also receive 1 L of NS IV infused over 1 to 2 hours immediately prior to each cidofovir infusion. If tolerated, a second liter may be administered over 1 to 3 hours at the start of cidofovir infusion or immediately following infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5c584eb-e1c7-46bb-9369-951500002ea5">Adenovirus infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adenovirus infection (treatment of disseminated, severe, or progressive disease [adjunctive agent] or preemptive therapy in hematopoietic cell transplant recipients</b>
<b>) (off-label use): IV:</b> 5 mg/kg/dose once weekly <b>or</b> 5 mg/kg once weekly for 2 doses then 5 mg/kg once every 2 weeks <b>or</b> 1 mg/kg/dose 3 times weekly; with concomitant probenecid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30859626','lexi-content-ref-30418684','lexi-content-ref-20837781','lexi-content-ref-30403300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30859626','lexi-content-ref-30418684','lexi-content-ref-20837781','lexi-content-ref-30403300'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="287f94df-8a83-4882-8ffc-2cd6e78932ed">BK virus infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>BK virus infection (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hemorrhagic cystitis, hematopoietic cell transplant recipients: </i>Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 3 to 5 mg/kg/dose every 1 to 2 weeks with concomitant probenecid <b>or</b> 0.5 to 1.5 mg/kg/dose 1 to 3 times weekly without probenecid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29190347','lexi-content-ref-29679772','lexi-content-ref-29797613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29190347','lexi-content-ref-29679772','lexi-content-ref-29797613'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intravesicular:</b> 5 mg/kg/dose (in 60 mL NS) instilled into bladder once weekly; retain for ≥1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29679772','lexi-content-ref-29797613','lexi-content-ref-31876431']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29679772','lexi-content-ref-29797613','lexi-content-ref-31876431'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Viremia or nephropathy, kidney transplant recipients:</i> Limited data available: IV: 0.25 to 1 mg/kg/dose every 1 to 3 weeks without probenecid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859620','lexi-content-ref-12686681','lexi-content-ref-15996251','lexi-content-ref-12544881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859620','lexi-content-ref-12686681','lexi-content-ref-15996251','lexi-content-ref-12544881'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2b9383d-1064-41d8-a904-c81cb7f0bf4c">Cytomegalovirus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (eg, treatment of invasive disease including retinitis and preemptive therapy in hematopoietic cell recipients) (alternative agent): IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Induction: 5 mg/kg/dose once weekly for 2 consecutive weeks, with concomitant probenecid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: 5 mg/kg/dose once every 2 weeks with concomitant probenecid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e623717f-8ad8-461a-8a9d-4edab7846a37">Herpes simplex virus infection, acyclovir-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus infection, acyclovir-resistant (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Mucosal infections: 5 mg/kg/dose once weekly for 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17461998','lexi-content-ref-11049772','lexi-content-ref-9502489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17461998','lexi-content-ref-11049772','lexi-content-ref-9502489'])">Ref</a></span>), then 5 mg/kg/dose once every 2 weeks for 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17461998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17461998'])">Ref</a></span>); with concomitant probenecid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9502489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9502489'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical</b> (off-label route): Mucocutaneous infections: Apply cidofovir 1% gel (extemporaneously prepared by a compounding pharmacy) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-9333146','lexi-content-ref-17284082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-9333146','lexi-content-ref-17284082'])">Ref</a></span>). Duration of therapy: 5 days; observe for 10 days following treatment; therapy may be repeated if necessary for up to 6 repetitive cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9333146','lexi-content-ref-17284082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9333146','lexi-content-ref-17284082'])">Ref</a></span>). A prolonged duration of 21 to 28 days or longer may be required for patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97c777df-e720-4db8-8277-210aa1890f45">Nonvariola orthopoxvirus infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonvariola orthopoxvirus infection (eg, mpox [monkeypox]) (alternative agent) (off-label use): Note: </b>Reserve use for patients with or at risk for severe disease. Use in combination with tecovirimat; only use as monotherapy in patients who have a contraindication to tecovirimat use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36862595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36862595'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Limited data available: 5 mg/kg once weekly for 2 doses, with concomitant probenecid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36862595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36862595'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990259"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Manufacturer's labeling:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:4em;">Preexisting renal impairment: Serum creatinine &gt;1.5 mg/dL, CrCl ≤55 mL/minute, or urine protein ≥100 mg/dL (≥2+ proteinuria): Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">Changes in renal function during therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">Serum creatinine increases by 0.3 to 0.4 mg/dL: Reduce dose to 3 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum creatinine increases ≥0.5 mg/dL or development of ≥3+ proteinuria: Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alternate dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9951427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9951427'])">Ref</a></span>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Given significant risk of nephrotoxicity, avoid use in renal impairment (CrCl ≤55 mL/minute) unless benefit outweighs the risk. Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes. Adjustment based on 5 mg/kg/dose. Induction doses should be given once weekly and maintenance doses every other week.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥1.3 mL/minute/<b>kg</b>: 5 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 1 to 1.2 mL/minute/<b>kg</b>: 4 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 0.8 to 0.9 mL/minute/<b>kg</b>: 3 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 0.7 mL/minute/<b>kg</b>: 2.5 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 0.5 to 0.6 mL/minute/<b>kg</b>: 2 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 0.4 mL/minute/<b>kg</b>: 1.5 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 0.2 to 0.3 mL/minute/<b>kg</b>: 1 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 0.1 mL/minute/<b>kg</b>: 0.5 mg/kg/dose with concomitant probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Dialyzable (~50%): Administer standard induction or maintenance dose 2 hours before hemodialysis without probenecid.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Dialyzable (minimal): 0.5 mg/kg/dose without probenecid.</p></div>
<div class="block doha drugH1Div" id="F50987427"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F151260"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum bicarbonate</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Hypotony of eye (can be severe: Intraocular pressure of 0 to 1 mm Hg), iritis, uveitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance, increased serum creatinine, nephrotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fanconi syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency</p></div>
<div class="block coi drugH1Div" id="F151274"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cidofovir or any component of the formulation; history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications; serum creatinine &gt;1.5 mg/dL; CrCl ≤55 mL/minute; urine protein ≥100 mg/dL (≥2+ proteinuria); use with or within 7 days of nephrotoxic agents; direct intraocular injection</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F151257"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Carcinogenic/teratogenic: <b>[US Boxed Warning]: Possibly carcinogenic and teratogenic based on animal data. May cause hypospermia.</b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Metabolic acidosis: Monitor for signs of metabolic acidosis; decreased sodium bicarbonate with proximal tubule injury and renal wasting syndrome (including Fanconi syndrome), as well as metabolic acidosis with hepatic impairment and pancreatitis (including some fatal cases) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Nephrotoxicity: <b>[US Boxed Warning]: Acute renal failure resulting in dialysis and/or contributing to death has occurred with as few as 1 or 2 doses of cidofovir. Renal function (serum creatinine and urine protein) must be monitored within 48 hours prior to each dose of cidofovir and the dose of cidofovir modified as appropriate.  Administration must be accompanied by oral probenecid and intravenous saline prehydration. </b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Neutropenia: <b>[US Boxed Warning]: Neutropenia has been reported; monitor neutrophil counts during therapy. </b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Ocular complications: Decreased intraocular pressure, sometimes associated with decreased visual acuity, uveitis, or iritis may occur; monitor intraocular pressure for and signs of iritis/uveitis during therapy. If uveitis or iritis occurs, consider treatment with topical corticosteroids with or without topical cycloplegic agents.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Contraindicated in patients with a baseline serum creatinine &gt;1.5 mg/dL, CrCl ≤55 mL/minute, or urine protein ≥100 mg/dL (≥2+ proteinuria); dosage adjustment or discontinuation of therapy may be required for changes in renal function during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Administration: For intravenous use only, <b>not</b> for direct intraocular injection; iritis, ocular hypotony, and permanent impairment of vision may occur.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Appropriate use: <b>[US Boxed Warning]: Indicated only for CMV retinitis treatment in patients with AIDS.</b></p></div>
<div class="block foc drugH1Div" id="F151268"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg/mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F151253"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323067"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cidofovir Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg/mL (per mL): $177.60 - $237.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866335"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg/mL (5 mL)</p></div>
<div class="block exp drugH1Div" id="F46170920"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">A 1% topical cidofovir gel may be prepared by using 5 mL of the 75 mg/mL cidofovir injection and combining with 32.5 mL of a propylene glycol-based jelly. Of note, propylene glycol may increase the absorption and bioavailability of cidofovir when used on abraded skin (McElhiney 2006).</p></div>
<div class="block admp drugH1Div" id="F52612418"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer by IV infusion over 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Intralesional (recurrent respiratory papillomatosis): Administer in appropriate setting by experienced surgeon, typically following surgical intervention/lesion debulking. Volume and number of injections per treatment variable, based on extent of disease and size of airway; recommended volumes are ≤2 mL for children and ≤4 mL for adolescents; larger volumes have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23113383','lexi-content-ref-23070868','lexi-content-ref-15545589','lexi-content-ref-18700421','lexi-content-ref-12972938','lexi-content-ref-21519834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23113383','lexi-content-ref-23070868','lexi-content-ref-15545589','lexi-content-ref-18700421','lexi-content-ref-12972938','lexi-content-ref-21519834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intravesicular (hemorrhagic cystitis): Instill into bladder via Foley catheter slowly (eg, over 15 minutes). If indwelling catheter is in place, clamp catheter for ≥1 hour after instillation. For patients who do not require indwelling catheter, Foley catheter can be removed after drug administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16755571','lexi-content-ref-29388318','lexi-content-ref-29776868','lexi-content-ref-19203733','lexi-content-ref-25882393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16755571','lexi-content-ref-29388318','lexi-content-ref-29776868','lexi-content-ref-19203733','lexi-content-ref-25882393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Topical (mucocutaneous herpes simplex virus): Apply topically to affected area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F802620"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV infusion only. Infuse over 1 hour. Administer with concomitant probenecid. Hydrate with 1 L of NS IV over 1 to 2 hours immediately prior to cidofovir infusion. If tolerated, a second liter may be administered over a 1- to 3-hour period at the start of or immediately following cidofovir infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> Off-label route: An extemporaneously prepared gel may be prepared by a compounding pharmacy and applied topically for mucocutaneous infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23974309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23974309'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravesicular:</b> Off-label route: Instill into bladder via Foley catheter over 15 minutes. If indwelling catheter is in place, clamp catheter for at least 1 hour after instillation. Remove Foley catheter after drug administration for patients who do not require indwelling catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16755571','lexi-content-ref-19203733','lexi-content-ref-31876431']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16755571','lexi-content-ref-19203733','lexi-content-ref-31876431'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49130930"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F151283"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F). Admixtures in D5<sup>1</sup>/<sub>4</sub>NS, D5W, or NS may be stored for ≤24 hours under refrigeration; however, admixtures must be administered within 24 hours of preparation.</p></div>
<div class="block usep drugH1Div" id="F53566059"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS (FDA approved in adults). Has also been used for treatment of adenovirus, BK virus, and acyclovir-resistant herpes simplex virus and intralesionally for the treatment of recurrent respiratory papillomatosis.</p></div>
<div class="block cyt drugH1Div" id="F13299042"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3; <b>Inhibits</b> MRP2</p></div>
<div class="block dri drugH1Div" id="F151262"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: May enhance the adverse/toxic effect of Cidofovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Cidofovir may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Cidofovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49296628"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In animal studies, cidofovir caused hypospermia.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 1 month after the last cidofovir dose. Males should use a barrier contraceptive during therapy and for 3 months following the last dose of cidofovir.</p></div>
<div class="block pri drugH1Div" id="F151276"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cidofovir was teratogenic in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">The indications for treating CMV retinitis during pregnancy are the same as in nonpregnant HIV infected woman; however, systemic therapy should be avoided during the first trimester when possible. When therapy is needed to treat maternal infection, use of cidofovir is not recommended (HHS [Adult OI 2021]). Cidofovir is not recommended as an alternative therapy to treat patients with mpox (monkeypox) during the first trimester (CDC 2022).</p></div>
<div class="block mopp drugH1Div" id="F53566034"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum creatinine and urine protein (at baseline and within 48 hours of each dose, CBC with differential/neutrophil count (prior to each dose), liver function tests (weekly),(Norris 2019) urine glucose, serum phosphate, serum bicarbonate, uric acid; intraocular pressure and visual acuity, signs and symptoms of uveitis/iritis; signs and symptoms of metabolic acidosis.</p></div>
<div class="block rerp drugH1Div" id="F56581031"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Therapeutic drug monitoring is not routine practice; data are very limited (n=8 children with adenovirus viremia) and potentially impacted by confounders (Neant 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Adenovirus infections: AUC<sub>24</sub> ≥19.1 mg•hour/L (Neant 2018).</p></div>
<div class="block pha drugH1Div" id="F151256"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cidofovir is converted to cidofovir diphosphate (the active intracellular metabolite); cidofovir diphosphate suppresses CMV replication by selective inhibition of viral DNA synthesis. Incorporation of cidofovir diphosphate into growing viral DNA chain results in viral DNA synthesis rate reduction.</p></div>
<div class="block phk drugH1Div" id="F151273"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">The following pharmacokinetic data are based on a combination of cidofovir administered with probenecid unless otherwise specified:</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Does not cross significantly into cerebrospinal fluid.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents ≤14 years: 0.591 L/kg (with probenecid) (Caruso Brown 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.41 L/kg (with probenecid); 0.537 L/kg (without probenecid).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;6%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal; phosphorylation occurs intracellularly to the active metabolite cidofovir diphosphate.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, plasma: Mean range: 2.4 to 3.2 hours (Cundy 1995; Lalezari 1995); intracellular elimination half-lives of metabolites are longer (range: 24 to 87 hours) (Lea 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (70% to 85% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:6em;">Renal clearance without probenecid: 150±26.9 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">Renal clearance with probenecid: 98.6±27.9 mL/minute/1.73 m<sup>2</sup>.</p></div>
<div class="block phksp drugH1Div" id="F51220834"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance decreases proportionally with CrCl.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038561"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Empovir | Vistide</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir tillomed</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir tillomed | Vistide</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir tillomed | Sidovis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir macure | Vistide</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir tillomed | Vistide</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir macure | Cidofovir tillomed macure</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir tillomed | Vistide</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vistide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir macure | Vistide</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cidofovir tillomed | Vistide</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Sidovis</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23113383">
<a name="23113383"></a>Ablanedo-Terrazas Y, Soda-Merhy A, Hernández-Palestina M, Ormsby CE, Reyes-Terán G. Intralesional cidofovir in severe juvenile respiratory papillomatosis. <i>B-ENT</i>. 2012;8(3):197-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23113383/pubmed" id="23113383" target="_blank">23113383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9544639">
<a name="9544639"></a>Akler ME, Johnson DW, Burman WJ, et al, “Anterior Uveitis and Hypotony After Intravenous Cidofovir for the Treatment of Cytomegalovirus Retinitis,” <i>Ophthalmology</i>, 1998, 105(4):651-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9544639/pubmed" id="9544639" target="_blank">9544639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18307672">
<a name="18307672"></a>Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al, "High-Risk Adenovirus-Infected Pediatric Allogeneic Hematopoietic Progenitor Cell Transplant Recipients and Preemptive Cidofovir Therapy," <i>Pediatr Transplant</i>, 2008, 12(2):219-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/18307672/pubmed" id="18307672" target="_blank">18307672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17461998">
<a name="17461998"></a>Andrei G, Fiten P, Goubau P, et al. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. <i>Transpl Infect Dis</i>. 2007;9(2):126-131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/17461998/pubmed" id="17461998" target="_blank">17461998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19344337">
<a name="19344337"></a>Araya CE, Garin EH, Neiberger RE, Dharnidharka VR. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. <i>Pediatric Transplantation</i>. 2010;14:145-150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19344337/pubmed" id="19344337" target="_blank">19344337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18537898">
<a name="18537898"></a>Araya CE, Lew JF, Fennell RS, et al, "Intermediate Dose Cidofovir Does Not Cause Additive Nephrotoxicity in BK Virus Allograft Nephropathy," <i>Pediatr Transplant</i>, 2008, 12(7):790-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/18537898/pubmed" id="18537898" target="_blank">18537898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19392729">
<a name="19392729"></a>Bhadri VA, Lee-Horn L, Shaw PJ. Safety and tolerability of cidofovir in high-risk pediatric patients. <i>Transpl Infect Dis</i>. 2009;11(4):373-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19392729/pubmed" id="19392729" target="_blank">19392729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193450">
<a name="19193450"></a>Bielecki I, Mniszek J, Cofala M. Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. <i>International Journal of Pediatric Otorhinolaryngology</i>. 2009;73:681-684.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19193450/pubmed" id="19193450" target="_blank">19193450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11081393">
<a name="11081393"></a>Blot N, Schneider P, Young P, et al. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. <i>Bone Marrow Transplant</i>. 2000;26(8):903-905. doi:10.1038/sj.bmt.1702591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/11081393/pubmed" id="11081393" target="_blank">11081393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16755571">
<a name="16755571"></a>Bridges B, Donegan S, Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. <i>Am J Hematol.</i> 2006;81(7):535-537. doi:10.1002/ajh.20567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/16755571/pubmed" id="16755571" target="_blank">16755571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9951427">
<a name="9951427"></a>Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. <i>Clin Pharmacol Ther.</i> 1999;65(1):21-28. doi:10.1016/S0009-9236(99)70118-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9951427/pubmed" id="9951427" target="_blank">9951427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11734717">
<a name="11734717"></a>Bryant P, Sasadeusz J, Carapetis J, Waters K, Curtis N. Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. <i>Pediatr Infect Dis J</i>. 2001;20(11):1083-1086. doi:10.1097/00006454-200111000-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/11734717/pubmed" id="11734717" target="_blank">11734717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25733509">
<a name="25733509"></a>Caruso Brown AE, Cohen MN, Tong S, et al. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. <i>Antimicrob Agents Chemother</i>. 2015;59(7):3718-3725. doi:10.1128/AAC.04348-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/25733509/pubmed" id="25733509" target="_blank">25733509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Clinical considerations for monkeypox in people who are pregnant or breastfeeding. <a href="https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html" target="_blank">https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html</a>. Updated July 18, 2022. Accessed July 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29190347">
<a name="29190347"></a>Cesaro S, Dalianis T, Hanssen Rinaldo C, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. <i>J Antimicrob Chemother.</i> 2018;73(1):12-21. doi:10.1093/jac/dkx324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/29190347/pubmed" id="29190347" target="_blank">29190347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19522651">
<a name="19522651"></a>Cesaro S, Hirsch HH, Faraci M, et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. <i>Clin Infect Dis</i>. 2009;49(2):233-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19522651/pubmed" id="19522651" target="_blank">19522651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23222380">
<a name="23222380"></a>Cesaro S, Pillon M, Tridello G, et al. Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir, a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i>. 2013;48:809-813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23222380/pubmed" id="23222380" target="_blank">23222380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16157264">
<a name="16157264"></a>Cesaro S, Zhou X, Manzardo C, et al, "Cidofovir for Cytomegalovirus Reactivation in Pediatric Patients After Hematopoietic Stem Cell Transplantation," <i>J Clin Virol</i>, 2005, 34(2):129-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/16157264/pubmed" id="16157264" target="_blank">16157264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11049772">
<a name="11049772"></a>Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. <i>Clin Infect Dis</i>. 2000;31(4):927-935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/11049772/pubmed" id="11049772" target="_blank">11049772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.1">
<a name="Avet.1"></a>Cidofovir (cidofovir) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.2">
<a name="Avet.2"></a>Cidofovir (cidofovir) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Cidofovir (cidofovir) [prescribing information]. Morgantown, WV: Mylan Institutional LLC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.2">
<a name="Mylan.2"></a>Cidofovir (cidofovir) [prescribing information]. Rockford, IL: Mylan Institutional LLC; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.3">
<a name="Mylan.3"></a>Cidofovir (cidofovir) [prescribing information]. Rockford, IL: Mylan Institutional LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29679772">
<a name="29679772"></a>Coomes EA, Wolfe Jacques A, Michelis FV, et al. Efficacy of cidofovir in treatment of BK virus-induced hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. <i>Biol Blood Marrow Transplant</i>. 2018;24(9):1901-1905. doi:10.1016/j.bbmt.2018.04.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/29679772/pubmed" id="29679772" target="_blank">29679772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7574510">
<a name="7574510"></a>Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. <i>Antimicrob Agents Chemother</i>. 1995;39(6):1247-1252. doi:10.1128/AAC.39.6.1247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/7574510/pubmed" id="7574510" target="_blank">7574510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23070868">
<a name="23070868"></a>Derkay CS, Volsky PG, Rosen CA, et al. Current use of intralesional cidofovir for recurrent respiratory papillomatosis. <i>Laryngoscope</i>. 2013;123(3):705-712. doi:10.1002/lary.23673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23070868/pubmed" id="23070868" target="_blank">23070868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17845926">
<a name="17845926"></a>Doan ML, Mallory GB, Kaplan SL, et al, "Treatment of Adenovirus Pneumonia With Cidofovir in Pediatric Lung Transplant Recipients," <i>J Heart Lung Transplant</i>, 2007, 26(9):883-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/17845926/pubmed" id="17845926" target="_blank">17845926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9331442">
<a name="9331442"></a>Ennis RD, Dahl TC. Stability of cidofovir in 0.9% sodium chloride injection for five days.<i> Am J Health Syst Pharm</i>. 1997;54(19):2204-2206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9331442/pubmed" id="9331442" target="_blank">9331442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19057462">
<a name="19057462"></a>Faraci M, Cuzzubbo D, Lanino E, et al, "Low Dosage Cidofovir Without Probenecid as Treatment for BK Virus Hamorrhagic Cystitis After Hemopoietic Stem Cell Transplant," <i>Pediatr Infect Dis J</i>, 2009, 28(1):55-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19057462/pubmed" id="19057462" target="_blank">19057462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25010830">
<a name="25010830"></a>Florescu DF, Chambers HE, Qiu F, et al. Cidofovir in pediatric solid organ transplant recipients: University of Nebraska experience. <i>Pediatr Infect Dis J</i>. 2015;34(1):47-51. doi:10.1097/INF.0000000000000487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/25010830/pubmed" id="25010830" target="_blank">25010830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20467354">
<a name="20467354"></a>Florescu DF, Islam MK, Mercer DF, et al. Adenovirus infections in pediatric small bowel transplant recipients. <i>Transplantation</i>. 2010;90(2):198-204. doi:10.1097/TP.0b013e3181e0de97<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/20467354/pubmed" id="20467354" target="_blank">20467354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859626">
<a name="30859626"></a>Florescu DF, Schaenman JM; AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13527. doi:10.1111/ctr.13527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/30859626/pubmed" id="30859626" target="_blank">30859626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29388318">
<a name="29388318"></a>Foster JH, Cheng WS, Nguyen NY, Krance R, Martinez C. Intravesicular cidofovir for BK hemorrhagic cystitis in pediatric patients after hematopoietic stem cell transplant. <i>Pediatr Transplant</i>. 2018;22(3):e13141. doi:10.1111/petr.13141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/29388318/pubmed" id="29388318" target="_blank">29388318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30175491">
<a name="30175491"></a>Gabardi S, Pavlakis M, Tan C, et al. New England BK consortium: regional survey of BK screening and management protocols in comparison to published consensus guidelines.<i> Transpl Infect Dis.</i> 2018;20(6):e12985. doi:10.1111/tid.12985<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/30175491/pubmed" id="30175491" target="_blank">30175491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27239277">
<a name="27239277"></a>Ganapathi L, Arnold A, Jones S, et al. Use of cidofovir in pediatric patients with adenovirus infection. <i>F1000Res</i>. 2016;5:758. doi:10.12688/f1000research.8374.2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/27239277/pubmed" id="27239277" target="_blank">27239277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29776868">
<a name="29776868"></a>Gander R, Asensio M, Guillén G, et al. Hemorrhagic cystitis after hematopoietic stem cell transplantation: A challenge for the pediatric urologist. <i>J Pediatr Urol</i>. 2018;14(5):366-373. doi:10.1016/j.jpurol.2018.03.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/29776868/pubmed" id="29776868" target="_blank">29776868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9785611">
<a name="9785611"></a>Garcia CR, Torriani FJ, and Freeman WR, “Cidofovir in the Treatment of Cytomegalovirus (CMV) Retinitis,” <i>Ocul Immunol Inflamm</i>, 1998, 6(3):195-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9785611/pubmed" id="9785611" target="_blank">9785611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30418684">
<a name="30418684"></a>González-Vicent M, Verna M, Pochon C, et al. Current practices in the management of adenovirus infection in allogeneic hematopoietic stem cell transplant recipients in Europe: the AdVance study.<i> Eur J Haematol.</i> 2019;102(3):210-217. doi:10.1111/ejh.13194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/30418684/pubmed" id="30418684" target="_blank">30418684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23070260">
<a name="23070260"></a>Graupp M, Gugatschka M, Kiesler K, Reckenzaun E, Hammer G, Friedrich G. Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis. <i>Eur Arch Otorhinolaryngol</i>. 2013;270:641-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23070260/pubmed" id="23070260" target="_blank">23070260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859620">
<a name="30859620"></a>Hirsch HH, Randhawa PS; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13528. doi:10.1111/ctr.13528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/30859620/pubmed" id="30859620" target="_blank">30859620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hitchcock.1">
<a name="Hitchcock.1"></a>Hitchcock MJ, Jaffe HS, Martin JC, et al, “Cidofovir, a New Agent With Potent Antiherpesvirus Activity,” <i>Antivir Chem Chemother</i>, 1996, 7:115-27.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29663594">
<a name="29663594"></a>Hiwarkar P, Kosulin K, Cesaro S, et al. Management of adenovirus infection in patients after haematopoietic stem cell transplantation: state-of-the-art and real-life current approach: a position statement on behalf of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation. <i>Rev Med Virol.</i> 2018;28(3):e1980. doi:10.1002/rmv.1980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/29663594/pubmed" id="29663594" target="_blank">29663594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12686681">
<a name="12686681"></a>Keller LS, Peh CA, Nolan J, Bannister KM, Clarkson AR, Faull RJ. BK transplant nephropathy successfully treated with cidofovir. <i>Nephrol Dial Transplant.</i> 2003;18(5):1013-1014. doi:10.1093/ndt/gfg061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/12686681/pubmed" id="12686681" target="_blank">12686681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22999487">
<a name="22999487"></a>Koskenvuo M, Dumoulin A, Lautenschlager I, et al. BK polyomavirus-associated hemorrhagic cystitis among pediatric allogeneic bone marrow transplant recipients: treatment response and evidence for nosocomial transmission. <i>J Clin Virol</i>. 2013;56(1):77-81. doi:10.1016/j.jcv.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/22999487/pubmed" id="22999487" target="_blank">22999487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15996251">
<a name="15996251"></a>Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. <i>Am J Transplant.</i> 2005;5(8):1997-2004. doi:10.1111/j.1600-6143.2005.00980.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/15996251/pubmed" id="15996251" target="_blank">15996251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7706804">
<a name="7706804"></a>Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. <i>J Infect Dis</i>. 1995;171(4):788-796. doi:10.1093/infdis/171.4.788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/7706804/pubmed" id="7706804" target="_blank">7706804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9525435">
<a name="9525435"></a>Lalezari JP, Holland GN, Kramer F, et al, “Randomized, Controlled Study of the Safety and Efficacy of Intravenous Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS,” <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>, 1998, 17(4):339-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9525435/pubmed" id="9525435" target="_blank">9525435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9333146">
<a name="9333146"></a>Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. <i>J Infect Dis</i>. 1997;176(4):892-898.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9333146/pubmed" id="9333146" target="_blank">9333146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8841740">
<a name="8841740"></a>Lea AP and Bryson HM, “Cidofovir,” <i>Drugs</i>, 1996, 52(2):225-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/8841740/pubmed" id="8841740" target="_blank">8841740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494896">
<a name="15494896"></a>Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. <i>Clin Infect Dis</i>. 2004;39(suppl 1):S248-S257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/15494896/pubmed" id="15494896" target="_blank">15494896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20837781">
<a name="20837781"></a>Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. <i>Blood</i>. 2010;116(25):5476-5485. doi:10.1182/blood-2010-04-259291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/20837781/pubmed" id="20837781" target="_blank">20837781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17284082">
<a name="17284082"></a>Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. <i>Drugs</i>. 2007;67(2):155-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/17284082/pubmed" id="17284082" target="_blank">17284082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9502489">
<a name="9502489"></a>LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. <i>Clin Infect Dis</i>. 1998;26(2):512-513. doi: 10.1086/517101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9502489/pubmed" id="9502489" target="_blank">9502489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15545589">
<a name="15545589"></a>Mandell DL, Arjmand EM, Kay DJ, Casselbrant ML, Rosen CA. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. <i>Arch Otolaryngol Head Neck Surg</i>. 2004;130(11):1319-1323. doi:10.1001/archotol.130.11.1319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/15545589/pubmed" id="15545589" target="_blank">15545589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23146063">
<a name="23146063"></a>Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). <i>Transpl Infect Dis</i>. 2012;14(6):555-563. doi:10.1111/tid.12022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23146063/pubmed" id="23146063" target="_blank">23146063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23974309">
<a name="23974309"></a>McElhiney L. Topical cidofovir for treatment of resistant viral infections. <i>Int J of Pharm Compd</i>. 2006;10(5):324-328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23974309/pubmed" id="23974309" target="_blank">23974309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18700421">
<a name="18700421"></a>McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. <i>Ann Otol Rhinol Laryngol</i>. 2008;117(7):477-483. doi:10.1177/000348940811700702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/18700421/pubmed" id="18700421" target="_blank">18700421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28231366">
<a name="28231366"></a>Meacham RK, Thompson JW. Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. <i>Ear Nose Throat J</i>. 2017;96(2):69-74. doi:10.1177/014556131709600209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/28231366/pubmed" id="28231366" target="_blank">28231366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17044537">
<a name="17044537"></a>Naiman AN, Ayari S, Nicollas R, et al, "Intermediate-Term and Long-Term Results After Treatment by Cidofovir and Excision in Juvenile Laryngeal Papillomatosis," <i>Ann Otol Rhinol Laryngol</i>, 2006, 115(9):667-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/17044537/pubmed" id="17044537" target="_blank">17044537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29860512">
<a name="29860512"></a>Neant N, Klifa R, Bouazza N, et al. Model of population pharmacokinetics of cidofovir in immunocompromised children with cytomegalovirus and adenovirus infection. <i>J Antimicrob Chemother</i>. 2018;73(9):2422-2429. doi:10.1093/jac/dky192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/29860512/pubmed" id="29860512" target="_blank">29860512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30551156">
<a name="30551156"></a>Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. <i>Clin Infect Dis</i>. 2019;68(1):1-4. doi:10.1093/cid/ciy867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/30551156/pubmed" id="30551156" target="_blank">30551156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30403300">
<a name="30403300"></a>Permpalung N, Mahoney MV, Alonso CD. Adjunctive use of cidofovir and intravenous immunoglobulin to treat invasive adenoviral disease in solid organ transplant recipients. <i>Pharmacotherapy</i>. 2018;38(12):1260-1266. doi:10.1002/phar.2194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/30403300/pubmed" id="30403300" target="_blank">30403300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12972938">
<a name="12972938"></a>Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. <i>Laryngoscope</i>. 2003;113(9):1583-1587. doi:10.1097/00005537-200309000-00032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/12972938/pubmed" id="12972938" target="_blank">12972938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36862595">
<a name="36862595"></a>Rao AK, Schrodt CA, Minhaj FS, et al. Interim clinical treatment considerations for severe manifestations of Mpox - United States, February 2023. <i>MMWR Morb Mortal Wkly Rep.</i> 2023;72(9):232-243. doi:10.15585/mmwr.mm7209a4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/36862595/pubmed" id="36862595" target="_blank">36862595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19203733">
<a name="19203733"></a>Rao KV, Buie LW, Shea T, et al. Intravesicular cidofovir for the management of BK virus-associated cystitis. <i>Biol Blood Marrow Transplant</i>. 2009;15(3):391-392. doi:10.1016/j.bbmt.2008.12.490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19203733/pubmed" id="19203733" target="_blank">19203733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25882393">
<a name="25882393"></a>Rascon J, Verkauskas G, Pasauliene R, Zubka V, Bilius V, Rageliene L. Intravesical cidofovir to treat BK virus-associated hemorrhagic cystitis in children after hematopoietic stem cell transplantation. <i>Pediatr Transplant</i>. 2015;19(4):E111-E114. doi:10.1111/petr.12477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/25882393/pubmed" id="25882393" target="_blank">25882393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30817026">
<a name="30817026"></a>Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13512. doi:10.1111/ctr.13512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/30817026/pubmed" id="30817026" target="_blank">30817026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33661334">
<a name="33661334"></a>Salamonowicz-Bodzioch M, Frączkiewicz J, Czyżewski K, et al. Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation. <i>Ann Hematol</i>. 2021;100(5):1283-1293. doi:10.1007/s00277-021-04454-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/33661334/pubmed" id="33661334" target="_blank">33661334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29797613">
<a name="29797613"></a>Schneidewind L, Neumann T, Schmidt CA, Krüger W. Comparison of intravenous or intravesical cidofovir in the treatment of BK polyomavirus-associated hemorrhagic cystitis following adult allogeneic stem cell transplantation-a systematic review. <i>Transpl Infect Dis.</i> 2018;20(4):e12914. doi:10.1111/tid.12914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/29797613/pubmed" id="29797613" target="_blank">29797613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32404785">
<a name="32404785"></a>Siew JX, Seah XFV, Chew YR, et al. Epidemiology of adenovirus infections and outcomes of cidofovir treatment in severely ill children. <i>Pediatr Infect Dis J</i>. 2020;39(10):907-913. doi:10.1097/INF.0000000000002726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/32404785/pubmed" id="32404785" target="_blank">32404785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9572540">
<a name="9572540"></a>Taskintuna I, Rahhal FM, Capparelli EV, et al, “Intravitreal and Plasma Cidofovir Concentrations After Intravitreal and Intravenous Administration in AIDS Patients With Cytomegalovirus Retinitis,” <i>J Ocul Pharmacol Ther</i>, 1998, 14(2):147-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9572540/pubmed" id="9572540" target="_blank">9572540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876431">
<a name="31876431"></a>Tooker GM, Stafford KA, Nishioka J, Badros AZ, Riedel DJ. Intravesicular cidofovir in the treatment of BK virus-associated hemorrhagic cystitis following hematopoietic stem cell transplantation. <i>Ann Pharmacother.</i> 2020;54(6):547-553. doi:10.1177/1060028019897896<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/31876431/pubmed" id="31876431" target="_blank">31876431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated November 18, 2021. Accessed February 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed February 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12544881">
<a name="12544881"></a>Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. <i>Transplantation</i>. 2003;75(1):105-112. doi:10.1097/00007890-200301150-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/12544881/pubmed" id="12544881" target="_blank">12544881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilead.1">
<a name="Gilead.1"></a>Vistide (cidofovir) [prescribing information]. Foster City, CA: Gilead; September 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28419263">
<a name="28419263"></a>Vora SB, Brothers AW, Englund JA. Renal toxicity in pediatric patients receiving cidofovir for the treatment of adenovirus infection. <i>J Pediatric Infect Dis Soc</i>. 2017;6(4):399-402. doi:10.1093/jpids/pix011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/28419263/pubmed" id="28419263" target="_blank">28419263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9588429">
<a name="9588429"></a>Whitley RJ, Jacobson MA, Friedberg DN, et al, “Guidelines for the Treatment of Cytomegalovirus Diseases in Patients With AIDS in the Era of Potent Antiretroviral Therapy: Recommendations of an International Panel. International AIDS Society-USA,” <i>Arch Intern Med</i>, 1998, 158(9):957-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9588429/pubmed" id="9588429" target="_blank">9588429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21519834">
<a name="21519834"></a>Wierzbicka M, Jackowska J, Bartochowska A, Józefiak A, Szyfter W, Kędzia W. Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis. <i>Eur Arch Otorhinolaryngol</i>. 2011;268:1305-1311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/21519834/pubmed" id="21519834" target="_blank">21519834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19801951">
<a name="19801951"></a>Williams KM, Agwu AL, Dabb AA, et al, "A Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral Infection," <i>J Pediatr Hematol Oncol</i>, 2009, 31(11):825-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19801951/pubmed" id="19801951" target="_blank">19801951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8862207">
<a name="8862207"></a>Yuan LC, Samuels GJ, Visor GC. Stability of cidofovir in 0.9% sodium chloride injection and in 5% dextrose injection. <i>Am J Health Syst Pharm</i>. 1996;53(16):1939-1943. doi:10.1093/ajhp/53.16.1939<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/8862207/pubmed" id="8862207" target="_blank">8862207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16732176">
<a name="16732176"></a>Yusuf U, Hale GA, Carr J, et al, "Cidofovir for the Treatment of Adenoviral Infection in Pediatric Hematopoietic Stem Cell Transplant Patients," <i>Transplantation</i>, 2006, 81(10):1398-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/16732176/pubmed" id="16732176" target="_blank">16732176</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13155 Version 182.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
